Tag: pancreatic

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) being held May 30 - June 3, 2014 in Chicago, Ill, describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Patients with pancreatic cancer may benefit from MLN0264, an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates or ADCs. Preclinical results of MLN0264 were presented at the International Conference on Molecular Targets and Cancer Therapeutics, held in the Hynes Convention Center in Boston, Massachusetts, USA, October 19-23, 2013